Cohort Study in Type 2 Diabetes in China (CCDC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01076023 |
Recruitment Status : Unknown
Verified February 2010 by China Cardiometabolic Registries.
Recruitment status was: Active, not recruiting
First Posted : February 25, 2010
Last Update Posted : February 15, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Type 2 Diabetes |
Study Type : | Observational |
Estimated Enrollment : | 1000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Comprehensive Cohort Study in Type 2 Diabetes With High Risk of Cardiovascular Disease in China |
Study Start Date : | February 2010 |
Actual Primary Completion Date : | October 2012 |
Estimated Study Completion Date : | March 2013 |

- Incidence of cardiovascular events, including fatal and non-fatal acute coronary syndromes (acute myocardial infarction [AMI] or unstable angina), fatal or non-fatal stroke, and other cardiovascular death. [ Time Frame: 12 months ]
- Outcomes of current anti-diabetic treatment [ Time Frame: 12 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patients who are 40 years of age or older
- Patients with confirmed diagnosis of type II diabetes
- Patients with 3 or more CVD risk factors or with confirmed/history of CAD or history of ischemic stroke
- Patients who have lab data within 30 days of baseline visit
- Patients who are willing to return for all follow up visits
Exclusion Criteria:
- Patients who are not willing or not able to return to the same hospital within 12 months after enrollment
- Patients who have life threatening or terminal disease, or are physically unable to make follow up visits every 6 months after enrollment
- Patients have severe heart failure (New York Heart Association [NYHA] Class 3-4)
- Patients with severe renal deficiency (creatinine clearance less than 30 ml/min)
- Patients who are not willing to sign informed consent form

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01076023
China, Shanghai | |
Weiqing Wang | |
Shanghai, Shanghai, China, 200025 |
Principal Investigator: | Guang Ning, MD | Shanghai JiaoTong University RuiJing Hospital |
Responsible Party: | China Cardiometabolic Registries |
ClinicalTrials.gov Identifier: | NCT01076023 |
Other Study ID Numbers: |
CCMR-301-CCDC CCDC ( Registry Identifier: CCMR ) |
First Posted: | February 25, 2010 Key Record Dates |
Last Update Posted: | February 15, 2013 |
Last Verified: | February 2010 |
Diabetes Cardiovascular disease Observational study China |
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |